drugset

drugset / Trial / NCT00721656

Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes

NCT00721656 ↗

Phase 2 Completed 80 enrolled Kissei Pharmaceutical Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of KLS-0611 compared to placebo in patients with dry eye syndromes.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KLS-0611	Unknown	—	—

Indications